Drugs that contain Fluticasone Propionate
1. List of Armonair Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7540282 | TEVA PHARM | Reservoir pressure system for medicament inhaler |
May, 2023
(28 days ago) | |
|
US7540282 (Pediatric) | TEVA PHARM | Reservoir pressure system for medicament inhaler |
Nov, 2023
(5 months from now) | |
| US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(1 year, 2 months from now) | |
|
US9616024 (Pediatric) | TEVA PHARM | Process for preparing a medicament |
Mar, 2025
(1 year, 8 months from now) | |
| US9463288 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(1 year, 11 months from now) | |
| US10765820 | TEVA PHARM | Dry powder inhalation apparatus |
May, 2025
(1 year, 11 months from now) | |
|
US9463288 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(2 years from now) | |
|
US10765820 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Nov, 2025
(2 years from now) | |
| US8651103 | TEVA PHARM | Dry powder inhalation apparatus |
Mar, 2028
(4 years from now) | |
|
US8651103 (Pediatric) | TEVA PHARM | Dry powder inhalation apparatus |
Sep, 2028
(5 years from now) | |
| US10195375 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2031
(7 years from now) | |
| US10022510 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(7 years from now) | |
| US9731087 | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(7 years from now) | |
| US10124131 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(7 years from now) | |
| US9216260 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jun, 2031
(8 years from now) | |
|
US10195375 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2031
(8 years from now) | |
|
US9731087 (Pediatric) | TEVA PHARM | Dose counter for inhaler having a bore and shaft arrangement |
Nov, 2031
(8 years from now) | |
|
US10124131 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Nov, 2031
(8 years from now) | |
|
US10022510 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Nov, 2031
(8 years from now) | |
|
US9216260 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Dec, 2031
(8 years from now) | |
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(8 years from now) | |
| US8978966 | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jan, 2032
(8 years from now) | |
| US8714149 | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Feb, 2032
(8 years from now) | |
|
US10561808 (Pediatric) | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jul, 2032
(9 years from now) | |
|
US8978966 (Pediatric) | TEVA PHARM | Dose counters for inhalers, inhalers and methods of assembly thereof |
Jul, 2032
(9 years from now) | |
|
US8714149 (Pediatric) | TEVA PHARM | Airflow adaptor for a breath-actuated dry powder inhaler |
Aug, 2032
(9 years from now) | |
| US9782551 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(12 years from now) | |
| US9782550 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2035
(12 years from now) | |
| US10918816 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Dec, 2035
(12 years from now) | |
|
US9782551 (Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(12 years from now) | |
|
US9782550 (Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(12 years from now) | |
|
US10918816 (Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Jun, 2036
(13 years from now) | |
| US10569034 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2036
(13 years from now) | |
|
US10569034 (Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2037
(13 years from now) | |
| US11351317 | TEVA PHARM | Drug delivery device with electronics |
Feb, 2038
(14 years from now) | |
|
US11351317 (Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Aug, 2038
(15 years from now) | |
| US11357935 | TEVA PHARM | Drug delivery device with electronics |
Sep, 2038
(15 years from now) | |
| US11000653 | TEVA PHARM | Inhaler |
Dec, 2038
(15 years from now) | |
|
US11357935 (Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Mar, 2039
(15 years from now) | |
|
US11000653 (Pediatric) | TEVA PHARM | Inhaler |
Jun, 2039
(16 years from now) | |
| US11344685 | TEVA PHARM | Drug delivery device with electronics |
Sep, 2039
(16 years from now) | |
|
US11344685 (Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Mar, 2040
(16 years from now) | |
| US11439777 | TEVA PHARM | Drug delivery device with electronics |
May, 2040
(16 years from now) | |
| US11464923 | TEVA PHARM | Inhaler system |
Jun, 2040
(17 years from now) | |
| US11173259 | TEVA PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(17 years from now) | |
|
US11439777 (Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Nov, 2040
(17 years from now) | |
|
US11464923 (Pediatric) | TEVA PHARM | Inhaler system |
Dec, 2040
(17 years from now) | |
|
US11173259 (Pediatric) | TEVA PHARM | Drug delivery device with electronics and power management |
Jan, 2041
(17 years from now) | |
| US11266796 | TEVA PHARM | Inhalation device with integrated electronics |
Feb, 2041
(17 years from now) | |
|
US11266796 (Pediatric) | TEVA PHARM | Inhalation device with integrated electronics |
Aug, 2041
(18 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 9, 2024 |
| New Strength (NS) | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR DIGIHALER family patents
90
United States
45
European Union
35
Japan
29
Spain
27
Israel
26
China
24
Korea, Republic of
21
Australia
20
EA
20
Denmark
19
Canada
19
Hong Kong
15
Poland
13
South Africa
10
Portugal
10
Hungary
9
Cyprus
7
United Kingdom
7
Slovenia
7
Taiwan
6
Peru
6
Austria
5
Uruguay
5
Germany
5
Mexico
5
Argentina
4
New Zealand
4
Brazil
3
Croatia
3
San Marino
3
RS
1
IB
1
Chile
1
Ukraine
1
Turkey
2. List of Flovent Hfa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7832351 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jun, 2023
(15 days from now) | |
|
US7832351 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Dec, 2023
(6 months from now) | |
| US7500444 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Feb, 2026
(2 years from now) | |
|
US7500444 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Aug, 2026
(3 years from now) | |
Market Authorisation Date: 14 May, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
FLOVENT HFA family patents
3
European Union
2
Cyprus
2
China
2
Denmark
2
Portugal
2
Spain
2
Japan
2
United States
2
United Kingdom
2
Hong Kong
1
Germany
1
Mexico
1
Canada
1
Brazil
1
Australia
1
South Africa
1
Austria
3. List of Xhance drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8327844 | OPTINOSE US INC | Nasal delivery method |
Oct, 2023
(4 months from now) | |
| US8522778 | OPTINOSE US INC | Nasal devices |
Apr, 2024
(10 months from now) | |
| US7975690 | OPTINOSE US INC | Nasal devices |
Dec, 2025
(2 years from now) | |
| US10124132 | OPTINOSE US INC | Nasal delivery |
Mar, 2027
(3 years from now) | |
| US11602603 | OPTINOSE US INC | Nasal delivery devices |
Oct, 2028
(5 years from now) | |
| US10076615 | OPTINOSE US INC | Nasal delivery |
Jul, 2029
(6 years from now) | |
| US8550073 | OPTINOSE US INC | Nasal delivery |
Oct, 2029
(6 years from now) | |
| US8978647 | OPTINOSE US INC | Nasal delivery |
Dec, 2030
(7 years from now) | |
| US10252010 | OPTINOSE US INC | Nasal delivery devices |
Feb, 2031
(7 years from now) | |
| US11033696 | OPTINOSE US INC | Nasal delivery devices |
May, 2033
(9 years from now) | |
| US10179216 | OPTINOSE US INC | Nasal delivery devices |
Jul, 2033
(10 years from now) | |
| US10478574 | OPTINOSE US INC | Nasal administration |
Nov, 2033
(10 years from now) | |
| US10076614 | OPTINOSE US INC | Nasal delivery devices |
Oct, 2034
(11 years from now) | |
| US10300229 | OPTINOSE US INC | Nasal delivery devices |
Jul, 2035
(12 years from now) | |
| US11554229 | OPTINOSE US INC | Nasal administration |
Feb, 2036
(12 years from now) | |
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway
Dosage: SPRAY, METERED;NASAL
XHANCE family patents
56
United States
30
European Union
29
United Kingdom
19
Japan
15
Australia
14
Spain
11
China
10
Canada
10
Denmark
9
IB
9
Poland
7
Russia
7
Hong Kong
7
Mexico
6
Korea, Republic of
6
New Zealand
6
Austria
5
Germany
5
South Africa
4
Singapore
4
Brazil
3
India
2
Portugal
2
Slovenia
1
Israel
1
Indonesia
1
Malaysia
1
Cyprus
1
Norway
1
Turkey
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic